VITRUVIAN BioMedical, Inc. is at the forefront of biotechnology, focusing on the development of innovative solutions for Alzheimer's Disease (AD). The company has secured an exclusive global license for a groundbreaking therapeutic vaccine, YM7555, which is designed to prevent AD by targeting the proteins ABeta and TAU. This gene-based DNA vaccine works by introducing a segment of the gene that codes for these proteins, prompting the body to generate an immune response that produces antibodies to reduce their accumulation in the brain. Notably, the vaccine elicits a Th2 immune response, minimizing inflammatory reactions, which is crucial for its efficacy. VITRUVIAN is also advancing other vaccine candidates, including YM3711, which specifically targets ABeta, and has developed proprietary delivery systems for DNA vaccines.

In addition to its vaccine initiatives, VITRUVIAN is working on a proprietary biomarker for early-stage Alzheimer's detection, which could lead to a diagnostic blood test. This biomarker has shown a significant increase in serum levels among early-stage AD patients compared to non-AD individuals, indicating its potential utility in identifying candidates for the therapeutic vaccine. The company's commitment to "Advanced Personalized Medicine" emphasizes the integration of genetic, protein, and other individual patient data to tailor healthcare solutions. As VITRUVIAN continues to innovate in the realms of diagnostics and therapeutics, it aims to enhance the effectiveness of treatments for Alzheimer's Disease and improve patient outcomes globally.

United States

VITRUVIAN BioMedical, Inc is a biotechnology company focused on a unique Business Strategy based on Early, Medium and Late Stage product development. We are committed to providing "Advance Personalized Medicine" to medical professionals and patients globally". Our strategy increases the goal of success and is implemented with key partners in the biotech and pharmaceutical industries.  
 
Our current focuse is on Alzheimer's Disease (AD) utilizing a breakthrough Therapeutic Vaccine which targets ABeta and TAU  and an AD Biomarker for early stage detection.

VITRUVIAN BioMedical, Inc

Company Details